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The approval of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in the treatment of metastatic colorectal
cancer (CRC) has expanded the armamentarium against this disease. This paper will review the historical progress and recent
clinical developments of anti-EGFR therapies in the treatment of metastatic CRC. Novel strategies of targeting the EGFR pathway
to improve eﬃcacy as well as ongoing research in identifying speciﬁc molecular predictors of response will be discussed.
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1.Introduction
A decade ago, the systemic treatment of colorectal cancer
(CRC)consistedonlyofﬂuoropyrimidine-basedchemother-
apy administered alone or in combination with either
oxaliplatin or irinotecan in an empirical fashion, guided by
serial measurements of radiological response. Owing to the
remarkable advances in our understanding of the molecular
mechanisms of carcinogenesis, target-based therapies are
now commonly used as in the treatment of many types of
cancer, including CRC. Cetuximab and panitumumab are
monoclonal antibody against the epidermal growth factor
receptor (EGFR) that has been approved for the treatment
of patients with metastatic CRC [1, 2]. The optimal clinical
application of anti-EGFR agents in the management of CRC
patients and the identiﬁcation of predictive markers are the
main focus of research in recent years. This article will
concentrate on the developments and controversies of anti-
EGFR therapy in the management of CRC.
2.EGFRasaTarget inColorectalCancer
The concept of manipulation of EGFR in the treatment of
epithelial malignancies such as colorectal and lung cancers
has actually been envisaged since the mid 1960s [1, 2]. It was
during that period that the EGFR protein was ﬁrst isolated,
characterized, and recognized as a potential therapeutic
target. Throughout the last 40 years, advances made in basic
and clinical research have enhanced our understanding of
this target, and many diﬀerent classes of EGFR inhibitors are
now at various stages of clinical development.
EGFR is a 170kD member of the ErbB receptor tyrosine
kinase family of signaling proteins, and its ligands include
epidermal growth factor (EGF), transforming growth factor-
α (TGF-α), heparin-binding EGF (HB-EGF), and amphireg-
ulin (AR). Ligand binding, dimerization, and phosphory-
lation of EGFR lead to activation of downstream proteins,
leading to a cascade mediating cell growth and survival [3].
Two diﬀerent anti-EGFR strategies are currently available in
the therapeutic armamentarium: (1) monoclonal antibodies
that prevent EGFR ligand binding and (2) tyrosine-kinase
inhibitors (TKIs) that block phosphorylation of the intra-
cellular tyrosine kinase component of the EGFR. Both of
these strategies dampen signal transduction through some
of the downstream pathways such as RAS/RAF/mitogen-
activated protein kinase (MAPK) and phosphoinositide 3-
kinase (PI3K)-AKT cascades, thus limiting cell growth,
proliferation, invasion, angiogenesis, and metastasis [3, 4].2 Journal of Oncology
Table 1: Comparison between cetuximab and panitumumab.
Cetuximab Panitumumab
Structure Chimeric IgG-1, Fully humanized: IgG-2
30% murine
Hypersensitivity reaction 3% 1%
Half life 5 days 7.5 days
Treatment schedule 1-2 weekly 2-weekly
Antibody-dependent cell Yes
No ADCC reported mediated cytotoxicity Fc Domain
(ADCC) of IgG-1
3. Anti-EGFRMonoclonal Antibodies
Cetuximab (chimeric IgG1 monoclonal antibody) and pani-
tumumab (fully humanized IgG2 monoclonal antibody) are
two anti-EGFR monoclonal antibodies currently approved
in the treatment of metastatic CRC. The structural diﬀer-
ence between the IgG-1-based cetuximab and IgG-2-based
panitumumab is believed to have implications on their
mechanisms of action. Preclinical studies have suggested
that the cetuximab molecule is able to induce antibody-
dependent cell-mediated cytotoxicity (ADCC) [4, 5], where
natural killer cells, monocytes, and eosinophils are recruited
to lyse the targeted cells (i.e., tumor cells). Being a chimeric
antibody, cetuximab is also associated with a slightly higher
incidence of hypersensitivity and infusional reactions when
compared with fully humanized panitumumab (see Table 1).
3.1. Cetuximab. Pharmacokinetics studies have shown that
cetuximab’s binding aﬃnity for EGFR was shown to be
one log higher than its natural ligand and its mechanism
of action is thought to be competitive inhibition of ligand
binding to EGFR. Cetuximab alone resulted in in vitro
and in vivo growth inhibition in multiple tumor types,
including CRCs [4, 5]. Cetuximab was able to enhance the
antitumoreﬀectofirinotecan,asevidentfromanexperiment
on the HT-29 CRC xenograft model, where cetuximab
and irinotecan given in combination resulted in a greater
degree of tumor growth delay than when either agent was
given alone [5]. Furthermore, cetuximab has been shown
to overcome acquired resistance against irinotecan in vivo.
This was shown as an experiment where the addition of
cetuximab resulted in shrinkage of tumor xenografts which
were otherwise progressing after previous treatment with
irinotecan.
The landmark BOND trial [2] randomized 329 patients
with metastatic CRC which were EGFR-positive and refrac-
tory to irinotecan, to either cetuximab alone or in com-
bination with irinotecan in a 2 : 1 ratio. EGFR positiv-
ity was deﬁned as 1+ staining by immunohistochemistry,
and “irinotecan-refractory” status was deﬁned as disease
progression on or within 3 months of irinotecan-based
therapy. Cross-over was allowed from the monotherapy arm
to the combination arm upon disease progression. Objective
response rate (ORR) was signiﬁcantly in favor of the
combination arm (22.9% versus 10.8%, P = .007). Fifty-six
patientswhowererandomizedtocetuximabaloneeventually
crossed over to the combination arm, while 3.6% and
35.7% of these patients achieved partial response and stable
disease, respectively. This study led to the US Food Drug
Administration (FDA) approval of cetuximab in patients
with irinotecan-refractory meta static CRC. Subsequently,
the NCIC-CO.17 study randomized patients who had failed
at least 2 lines of prior therapies, to either supportive care
or cetuximab alone [6]. In this study where no cross-over
was allowed, there was a statistically signiﬁcant advantage
in median overall survival (OS) favoring the cetuximab
arm (6.1 months) compared with supportive care (4.6
months). Partial responses occurred in 23 patients (8.0%)
in the cetuximab group but none in the group assigned to
supportive care alone (P < .001).
Cetuximab has also been investigated in the ﬁrst-line
setting. The “CRYSTAL” [7]s t u d yi sam u l t i c e n t r ep h a s e
III trial which randomized more than 1000 patients with
metastatic CRC, to either the “FOLFIRI” regimen alone
(Irinotecan, infusional 5-ﬂuorouracil and leucovorin in a
2-weekly schedule), or in combination with cetuximab at
a weekly schedule. The primary endpoint (progression-free
survival (PFS)) was met in the study, where patients ran-
domized to the combination arm had a signiﬁcantly longer
progression-free survival (8.9 months versus 8.0 months; P
= .036) than the chemotherapy alone arm, but there was no
diﬀerence in overall survival in the initial intention-to-treat
analysis. Response rate was also signiﬁcantly better in the
combination arm (46.9% versus 38.7%; P = .005), resulting
in a larger number of patients being down staged enough
to undergo resection of liver metastases (9.8% versus 4.5%).
The “OPUS” study [8] is another ﬁrst-line randomized
phase II study, which randomized 337 chemotherapy-nave
patients with metastatic CRC, to either the FOLFOX-4
regimen or in combination with cetuximab in a 1:1 fashion.
The overall RR was 45.6% in the combination arm versus
35.7% in FOLFOX-4 alone arm. In the “ACROBAT” study,
Tabernero et al. reported on 42 patients who were treated
with FOLFOX-4 plus cetuximab, showing a conﬁrmed ORR
of 81% [9]. Encouragingly, 10 patients (23%) underwent
resection of previously unresectable metastases, 8 of them
had liver metastases. The resection with curative intent rate
of 23% achieved in this study is therefore comparable with
the highest reported for unselected patients.
3.2. Panitumumab. The US FDA approval of panitumumab
was based on a pivotal multinational phase III study that
involved over 400 patients [10]. This study compared
panitumumab versus best supportive care (BSC), allowing
cross-over from the BSC arm to panitumumab upon dis-
ease progression. The median PFS time was 8 weeks for
panitumumab and 7.3 weeks for BSC. After a 12-month
followup period, response rates were 10% for panitumumab
and 0% for BSC (P < .0001). The lack of diﬀerence in OS
(hazard ratio HR 1.00; 95% conﬁdence interval, CI 0.82 to
1.22) maybe attributed to the cross-over design, where 76%
of patients in the BSC arm subsequently received panitu-
mumab. As expected with anti-EGFR therapies, skin-related
toxicities occurred in 90% of patients in the panitumumab
group but no patients had grade 3 or 4 infusional reactions.Journal of Oncology 3
4.EGFRTyrosineKinaseInhibitors
Although not approved for the treatment of CRC, small
molecule inhibitors of the EGFR tyrosine kinase (TKI) have
been shown to have meaningful activity in diﬀerent tumor
types such as lung and pancreatic cancer. In contrast to
EGFR monoclonal antibodies, the site of action of these
drugs is intracellular at the ATP-binding site of the EGFR TK
domain. Compared with monoclonal antibodies, TKIs may
potentially inhibit multiple targets and tend not to induce
receptor downregulation.
4.1. Geﬁtinib. Geﬁtinib is a low-molecular-weight competi-
tiveinhibitorofATP-bindingpocketoftheEGFRTKdomain
[11] ,w h i c hi sa p p r o v e df o rt h et r e a t m e n to fn o n s m a l lc e l l
lung cancer. Clinical trials of geﬁtinib as a single agent
in CRC reported no objective tumor responses [12–14]
however, a sizable proportion of patients did have disease
stabilization. A phase II trial which compared the 250mg
versus a 500mg daily dosing of geﬁtinib [15], reported 1
partial response in a patient who received the 500mg dose.
Pairedbiopsiespre-andposttreatmentbiopsiesperformedin
28patientsshowedthat84%hadnochangeorincreaseinthe
expression level of phosphorylated EGFR, MAP kinase, and
Ki67 after treatment. Geﬁtinib and chemotherapy in com-
bination have also been investigated in several trials, where
the response rates seemed to be superior to the historically
reported rates of chemotherapy alone [16–18]. However,
there were signiﬁcantly more toxicities particularly with
respect to neutropenia and diarrhea with the combination.
Studies combining geﬁtinib with irinotecan also resulted in
greater toxicity, with some trials requiring early termination.
4.2. Erlotinib. Erlotinib has also been studied in advanced
CRC. There have been mixed reports of some clinical activity
when used as a single agent. As with geﬁtinib, erlotinib
produced a higher response rate when combined with
chemotherapy. High incidence of toxicity was noted when
givenincombinationwithsystemicchemotherapy,especially
in two trials where erlotinib was given in combination with
FOLFOX and bevacizumab [19, 20], with the latter trial
having prematurely closed due to toxicity.
5. Incidenceand Implicationsof Skin Rash
Anti-EGFR monoclonal antibodies and EGFR TKIs are asso-
ciated with a distinctive skin rash. The rash is characterized
histologically as a neutrophilic inﬁltrate in perifollicular
areas within the basal layer of the skin, which is diﬀerent
from that seen in typical acne. Skin toxicity is generally
observed within 2 to 3 weeks after the start of treatment
and gradually resolves in most patients, even when anti-
EGFR treatment is continued. In the BOND study, the most
frequently observed adverse event to cetuximab was the
skin rash, and in the panitumumab study, Hecht et al. [21]
reported a 95% incidence of acneiform skin rash of any
grade. Grade 3 rash occurred in 3% of patients and none
e x p e r i e n c e dg r a d e4s k i nt o x i c i t i e s .A na s s o c i a t i o nb e t w e e n
the severity of acneiform rash and eﬃcacy to cetuximab has
beenwelldescribed.RetrospectiveanalysisoftheBONDdata
showed a clear association between higher grades of skin
reaction with RR and time to progression (TTP) [2]. This
association is also seen with panitumumab [10] and seems
to hold true in the treatment of tumors of other sites with
this class of agents.
The “EVEREST” study [22] was a phase I/II dose-esca-
lation study, where patients who were receiving cetuximab
were randomized at 22 days, to either standard dose of
weekly (250mg/m2/week) cetuximab or an escalating dose
of cetuximab until the development of grade 3 toxicity,
with a maximum ceiling dose of 500mg/m2/week. Skin and
tumor biopsies were obtained. Preliminary report suggested
that the PFS in standard-dose arm was 3.9 months and 4.8
months in the dose-escalated arm. Dose-related increases
in pharmacokinetic parameters (e.g., Cmax, AUC) were
observed in the escalated arm. The authors concluded that
cetuximab dose escalation up to 500mg/m2/w may improve




Combinations of multiple targeted agents with or without
the additional of chemotherapy have also been investigated.
T h eB O N D - 2t r i a l[ 23] randomized irinotecan-refractory
patients to either 2 drugs (bevacizumab and cetuximab)
or 3 drugs (bevacizumab, cetuximab and irinotecan). The
results were encouraging, with the 3-drug arm resulting in
a better TTP and ORR than the 2-drug arm. This study
also showed for the ﬁrst time that monoclonal antibodies in
combination could induce an ORR of 20% in the absence
of chemotherapy. Nonstatistical comparison with result of
theBOND-1studysuggestedthatbevacizumabmayenhance
the eﬀects of irinotecan-cetuximab combination, with an
ORR of 37% as compared to 23% reported for the cetux-
imab/irinotecan arm [2, 23] (see Table 2). Subsequent to the
BOND-2study,3otherrandomizedtrialshavebeenreported
on the feasibility of combining monoclonal antibodies in
the treatment of CRC. The PACCE study [24]r a n d o m -
ized 824 treatment-nave patients with metastatic CRC to
oxaliplatin-based chemotherapy plus bevacizumab, with or
without panitumumab, and 230 patients to irinotecan-
based chemotherapy plus bevacizumab with or without
panitumumab. The study was terminated at a preplanned
interim analysis after 231 events were reported in patients
who received oxaliplatin-based therapy, where a statistically
signiﬁcant increase in PFS was reported in the arm without
panitumumab. In contrast, the Dutch CAIRO-2 trial [25]
has a similar study design to the PACCE trial and involved
over 700 patients. Patients received capecitabine, oxaliplatin,
and bevacizumab with or without additional cetuximab. As
expected, preliminary result reported a signiﬁcantly higher
incidence of grade 3-4 skin rash in the cetuximab-containing
arm, without a statistically signiﬁcant diﬀerence in mortality
ineitherarm.TheCALGB/SWOG80405intergrouptrialwas
a 3-arm study, which randomized patients with metastatic
CRC to chemotherapy and cetuximab, chemotherapy and4 Journal of Oncology
Table 2: Nonstatistical comparison of the results of the BOND-2 [23] and BOND-1 study [1].
BOND2 BOND2 BOND1 BOND1
Cetuximab, irinotecan, and bevacizumab Cetuximab and bevacizumab Cetuximab and irinotecan Cetuximab alone
No. of Patients 43 40 218 111
Prior treatment with oxaliplatin (%) 87 89 62 64
Response rates (%) 37 20 23 11
Time to progression (months) 7.3 4.9 4.1 1.5
Median overall survival (months) 14.5 11.4 8.6 6.9
bevacizumab, or chemotherapy plus cetuximab and beva-
cizumab.Thisstudyhasbeensuspendedfollowingadecision
by the CALGB Data and Safety Monitoring Board as from
June 2008, pending a protocol revision in view of the data
on KRAS mutation (see below) [26]. The reason why the
PACCE study failed to demonstrate a survival advantage in
the panitumumab-bevacizumab arm remains unclear. It is
possible that the dose of the antibodies was inappropriate
leading to excessive toxicity and reduced eﬃcacy. Patient
selection has also proven critical in the optimal use of anti-
EGFR antibodies as the use of EGFR staining to predict
response and outcome has been severely challenged. Thus,
a combination approach of targeted agents in metastatic
CRC remains controversial and it is the consensus among
gastrointestinal oncologists that such an approach remains
experimental.
7. EGFRExpressionin Colorectal Cancer
EGFR as determined by immunohistochemical (IHC) meth-
ods was the ﬁrst biomarker investigated as a potential predic-
tor of response. It is overexpressed in over 80% of colorectal
cancers [27]. However, EGFR expression as measured by
immunohistochemistry does not predict clinical beneﬁt [28,
29]. Initial observations in a small retrospective series by
Lenz et al. [30] noted that more than 20% of EGFR-negative
patients developed major objective responses. An extensive
retrospective analysis was reported in 2005 by Chung et al.
[29].Theyreported aresponse rateof25% in EGFR-negative
patients (4 out of 16) given cetuximab and irinotecan. This
wascomparableandindistinguishablefromtheresponserate
of23%seenintwoseparateclinicaltrialswithEGFR-positive
patients [1, 31]. Given this data, immunohistochemical
(IHC) demonstration of EGFR expression is no longer
required before starting cetuximab therapy in practice.
Similarly, in the phase II trial, the response to treatment with
panitumumab in patients with metastatic CRC was similar,
irrespective of the level of EGFR protein expression assessed
by IHC analysis [32].
8.PotentialPredictorsof Response to
Anti-EGFR Therapy
8.1. Activating EGFR Gene Mutations. There has been much
interest in determining whether EGFR gene mutations may
play a role in aﬀecting response to cetuximab or panitum-
umab. Previous research in nonsmall cell lung cancer [33]
has shown that EGFR TK mutations predict beneﬁt from
EGFR TKIs. However, several retrospective studies on tumor
biopsies and cell lines found that EGFR gene mutations in
CRC are extremely rare [34, 35]. No signiﬁcantly diﬀerent
gene mutations were found between responders and nonre-
sponders to treatment.
8.2. EGFR Gene Ampliﬁcation. It has been hypothesized that
DNA is a more stable molecule than a protein and thus
EGFR gene copy number maybe more accurate reﬂection
of the EGFR status than IHC expression [36]. In a cohort
of patients treated with cetuximab or panitumumab, EGFR
gene ampliﬁcation with increased copy number has been
shown to signiﬁcantly correlate with objective response to
treatment [36]. This raises the possibility that patients with
high EGFR copy number may be more likely to respond to
treatment with anti-EGFR therapies.
8.3.KRASGeneMutation. KRASisaguanosinetriphosphate
(GTP)-binding protein that acts as a critical on-oﬀ switch
in cellular growth and survival pathways. It plays a key role
in the RAS/MAPK signally pathway located downstream of
many growth factor receptors, including EGFR, and involved
in carcinogenesis. Mutations of KRAS that result in the con-
stitutive activation of MAPK pathway downstream occurs in
about40%ofcolorectalcancers[37].Aretrospectiveanalysis
reported by Li` evre et al. [38] analyzed tumor samples from
30 patients treated with cetuximab. A KRAS mutation was
found in 13 tumors (43%) and was signiﬁcantly associated
with absence of response to cetuximab. None of the patients
with response to cetuximab harbored a KRAS mutation.
The overall survival of patients without KRAS mutation
was signiﬁcantly higher compared with those patients with
am u t a t e dt u m o r( P = .016; median survival 16.3 versus
6.9 months). An increase in EGFR copy number was also
signiﬁcantly associated with objective tumor response.
It has been hypothesized that irrespective of the level
of EGFR expression, the presence of a KRAS mutation is
associated with a constitutive activation of the RAS/MAPK
pathway, leading to cell proliferation which cannot be signi-
ﬁcantly inhibited by cetuximab. KRAS mutations have also
been implicated in resistance against EGFR TKIs in lung
adenocarcinomas [39].
Large scale retrospective reviews retrieved archived tu-
mor tissue from prior cetuximab and panitumumab trials.
KRASmutationanalysiswasperformedtestedintumorsam-
ples collected from over 1000 participants of the “CRYSTAL”Journal of Oncology 5
[8], “OPUS” [40], NCIC-CO.17 trial [41] and panitumumab
trials [42]. Beneﬁcial eﬀects of anti-EGFR antibodies were
limited to a subgroup of patients with wild-type KRAS
tumors. This has led to the recommendation that all patients
with advanced CRC who are being considered for cetuximab
or panitumumab should undergo KRAS testing, and if the
cancer bears a mutated KRAS gene, they should not receive
an antibody that targets EGFR.
9. Conclusion
Throughout the last decade, signiﬁcant advancement in our
understanding of the molecular mechanisms of metastatic
CRC has been made. Anti-EGFR monoclonal antibodies
approvedforuseinthemetastaticsettinghavebroadenedthe
therapeutic armamentarium in the treatment of metastatic
CRC. The most eﬀective sequence and combinations of anti-
EGFR therapy with chemotherapy and, or bevacizumab in
order to achieve cytotoxic potentiation with limited toxicity
need to be addressed. Advances made in the identiﬁcation
of predictive biomarkers such as KRAS mutations allow us
to select distinct groups of patients who are most likely to
beneﬁt from cetuximab therapy.
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